Distribution of sirolimus in rat tissue

Clinical Biochemistry

Volumn 30, Issue 2, 1997, Pages 135-142

  Napoli, Kimberly L ^a   Wang, Mou Er ^a   Stepkowski, Stanislaw M ^a   Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

administration route; concentration; distribution; rapamycin; rat; sirolimus; tissue; whole blood

Indexed keywords

CYCLOSPORIN; RAPAMYCIN;

ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CELL CYCLE G1 PHASE; CONCENTRATION RESPONSE; DATA ANALYSIS; DEMETHYLATION; DRUG DISTRIBUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; OXYGEN SATURATION; PARTITION COEFFICIENT; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

ANIMALS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; INTESTINES; KIDNEY; LIVER; LUNG; MALE; MUSCLES; MYOCARDIUM; POLYENES; RATS; RATS, WISTAR; REGRESSION ANALYSIS; SIROLIMUS; TESTIS; TISSUE DISTRIBUTION;

EID: 0030938258     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(96)00157-9     Document Type: Article

References (30)

1. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22.989), a new antifungal antibiotic: I Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975; 28: 721-6.
2. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new anti-fungal antibiotic II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975; 28: 727-32.
3. Kimball P, Kerman R, Kahan B. Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation 1991; 51: 486-90.
4. Kahan B, Gibbons S, Tejpal N, Stepkowski S, Chou T. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991; 51: 232-9.
5. Morris R, Meiser B, Wu J, Shorthouse R, Wang J. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. Transplant Proc 1991; 23: 521-4.
6. Robertson A, Plenter R, Francis D, Clunie G. Synergistic prolongation of renal allograft survival with cyclosporine and rapamycin. Transplant Proc 1993; 25: 2898-9.
7. Wang M, Tu Y, Stepkowski S, Kahan B. Effect of cyclosporine alone or in combination with rapamycin and brequinar on survival of hamster heart xenograft in rats. Transplant Proc 1993; 25: 2876-7.
8. Yakimets W, Lakey J, Yatscoff R, et al. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine at low doses. Transplantation 1993; 56: 1293-8.
9. Dias V, Yatscoff R. Investigation of rapamycin transport and uptake across absorptive human intestinal cell monolayers. Clin Biochem 1994; 27: 31-6.
10. Yatscoff R, LeGatt D, Keenen R, Chackowsky P. Blood distribution of rapamycin. Transplantation 1993; 56: 1202-6.
11. Yatscoff R, Wang P, Chan K, Hicks D, Zimmerman J. Rapamycin: Distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit 1995; 17: 666-71.
12. Christians U, Sattler M, Schiebel H, et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos 1992; 20: 186-91.
13. Sattler M, Guengerich F, Yun C-H, Christians U, Sewing K-FR. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20: 753-61.
14. Fryer J, Yatscoff R, Pascoe E, Thliveris J. The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in the rabbit heterotopic heart transplant model. Transplantation 1993; 55: 340-55.
15. Granger D, Cromwell J, Chen S, et al. Prolongation of renal allograft survival in a large animal model by oral rapamycin therapy. Transplantation 1995; 59: 183-6.
16. Honcharik H, Fryer J, Yatscoff R. Pharmacokinetics of rapamycin: single-dose studies in the rabbit. Ther Drug Monit 1992; 14: 475-8.
17. Supko J, Malspeis L. Dose-dependent pharmacokinetics of rapamycin-28-N,N dimethylglycinate in the mouse. Cancer Chemother Pharmacol 1994; 33: 325-30.
18. Napoli K, Kahan B. Sample clean-up and high-performance liquid chromatographic techniques for measurement of whole blood rapamycin concentrations. J Chrom B 1994; 654: 111-20.
19. Shargel L, Yu A. Applied Biopharmaceutics and Pharmacokinetics. 3rd ed. Norwalk, CT: Appleton and Lange, 1993.
20. DiJoseph J, Russo R, Cochran D. Osmotic pump delivery of rapamycin. Transplantation 1993; 55: 450-2.
21. Wacher V, Liu T, Roberts J, Ascher N, Benet L. Time course of cyclosporine and its metabolites in blood, liver and spleen or naive Lewis rats: comparison with preliminary data obtained in transplanted animals. Biopharm & Drug Dispos 1995; 16: 303-12.
22. Piekoszewski W, Chow F, Jusko W. Disposition of tacrolimus (FK 506) in rabbits: role of red blood cell binding in hepatic clearance. Drug Metab Dispos 1993; 21: 690-8.
23. Arceci RJ, Stieglittz K, Bierer BE. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 1992; 80: 1528-36.
24. Naito M, Tsuge H, Kuroko C, Koyama T, Tomida A, Tatsuta T, Heike Y, Tsuruo T. Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-016 and synergistic modulation of multidrug resistance. J Natl Can Inst 1993; 85: 311-6.
25. Ochiai T, Gunji Y, Nagata M, Akitoshi K, Isono K. Effects of rapamycin in experimental allografting. Transplantation 1993; 56: 15-9.
26. Knight R, Ferraresso M, Serino F, Katz S, Lewis R, Kahan BD. Low-dose rapamycin potentiates the effects of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model. Transplantation 1993; 55: 947-9.
27. Tjia J, Webber I, Back D. Cyclosporin metabolism by the gastrointestinal mucosa. Br J Clin Pharmac 1991; 31: 344-6.
28. Webber I, Peters W, Back D. Cyclosporin metabolism by human gastrointestinal mucosal microsomes. Br J Clin Pharmac 1992; 33: 661-4.
29. Kolars J, Stetson P, Rush B, et al. Cyclosporine metabolism by P450IIIA in rat enterocytes - Another determinant of oral bioavailability? Transplantation 1992; 53: 596-602.
30. Kronbach T, Fischer V, Meyer U. Cyclosporine metabolism in human liver: Identification of a cytochrome CYP3 gene family as the major cyclosporine-metabolizing enzyme explains interaction of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630-5.